ANEUVO Company Profile
Background
Overview
ANEUVO is a bioelectronic medical device company dedicated to developing advanced technologies and therapies aimed at assisting patients with diseases and injuries unresponsive to conventional medical treatments. Established in 2016, the company focuses on pioneering neuromodulation solutions to address complex neurological conditions.
Mission and Vision
ANEUVO's mission is to restore functional independence, enhance quality of life, and foster a healthier, more equitable world for individuals living with disabling diseases and conditions. The company's vision centers on transforming the treatment landscape for challenging medical conditions through innovative neuromodulation technologies.
Primary Area of Focus
The company's primary focus is on developing non-invasive neuromodulation therapies, particularly targeting spinal cord injuries (SCI). Their flagship product, the ExaStim® Stimulation System, is designed to improve or restore motor function in individuals with SCI.
Industry Significance
ANEUVO holds a significant position in the medical device industry by addressing unmet needs in neurorehabilitation. Their innovative approach offers a non-invasive alternative to traditional treatments, potentially revolutionizing the management of spinal cord injuries and similar conditions.
Key Strategic Focus
Core Objectives
ANEUVO aims to develop and commercialize non-invasive neuromodulation therapies that restore motor function and improve the quality of life for individuals with spinal cord injuries. The company is committed to expanding access to these therapies through both clinical and home-based applications.
Specific Areas of Specialization
The company specializes in neuromodulation technologies, focusing on spinal cord stimulation to facilitate neurorehabilitation. Their expertise encompasses bioelectronics, neural prosthetics, and bio-signal processing.
Key Technologies Utilized
ANEUVO employs advanced bioelectronic systems and proprietary programming software to deliver targeted spinal cord stimulation. The ExaStim® device utilizes a 16-channel multi-electrode array to non-invasively stimulate nerves along the spinal cord and dorsal roots.
Primary Markets Targeted
The primary market for ANEUVO includes individuals with chronic, non-progressive neurological deficits resulting from incomplete spinal cord injuries. The company is also expanding its reach to healthcare professionals and rehabilitation centers seeking innovative therapeutic solutions.
Financials and Funding
Funding History
ANEUVO has secured multiple funding rounds to support its growth and product development. In March 2026, the company closed a Series C funding round of $22 million, led by Catcher Technology Co., Ltd., with participation from additional new investors. This funding is intended to strengthen manufacturing capabilities, quality systems, and regulatory initiatives.
Total Funds Raised
The total funds raised by ANEUVO amount to $1.46 million.
Notable Investors
Catcher Technology Co., Ltd. is a notable investor in ANEUVO, leading the Series C funding round in March 2026.
Intended Utilization of Capital
The capital raised is allocated towards scaling manufacturing operations, enhancing quality systems, advancing regulatory processes, and supporting disciplined commercialization expansion in approved markets.
Pipeline Development
Key Pipeline Candidates
The primary pipeline candidate is the ExaStim® Stimulation System, a non-invasive neuromodulation device designed to improve motor function in individuals with spinal cord injuries.
Stages of Clinical Trials or Product Development
ExaStim® has completed clinical testing as part of ANEUVO's nationwide, double-blind ASPIRE™ clinical trial. The device has received FDA Breakthrough Device Designation and CE Mark certification, indicating its readiness for clinical and home use.
Target Conditions
The ExaStim® Stimulation System targets spinal cord injuries, aiming to restore motor function and improve quality of life for affected individuals.
Relevant Timelines for Anticipated Milestones
ANEUVO plans for broader market expansion of ExaStim® in 2026, following its initial availability in targeted centers throughout Europe.
Technological Platform and Innovation
Proprietary Technologies
ANEUVO's proprietary technology includes the ExaStim® Stimulation System, which delivers non-invasive spinal cord stimulation through a 16-channel multi-electrode array. The system is controlled via proprietary programming software on a mobile digital device.
Significant Scientific Methods
The company employs advanced bioelectronic systems and bio-signal processing techniques to deliver targeted spinal cord stimulation. Their approach integrates neuromodulation with rehabilitation practices to enhance motor function recovery.
Leadership Team
Yi-Kai Lo, PhD
- Position: Chief Executive Officer and Co-founder
- Professional Background: Dr. Lo is a researcher and engineer with expertise in bioengineering. He co-founded ANEUVO in 2016 and has published over 40 journal and conference papers.
- Key Contributions: Dr. Lo developed the first fully integrated 1024-channel system-on-a-chip for epi-retinal prostheses and has been instrumental in advancing the company's neuromodulation technologies.
